Literature DB >> 15604208

Leiomyoma and myometrial gene expression profiles and their responses to gonadotropin-releasing hormone analog therapy.

Xiaoping Luo1, Li Ding, Jingxia Xu, R Stan Williams, Nasser Chegini.   

Abstract

Gene microarray was used to characterize the molecular environment of leiomyoma and matched myometrium during growth and in response to GnRH analog (GnRHa) therapy as well as GnRHa direct action on primary cultures of leiomyoma and myometrial smooth muscle cells (LSMC and MSMC). Unsupervised and supervised analysis of gene expression values and statistical analysis in R programming with a false discovery rate of P < or = 0.02 resulted in identification of 153 and 122 differentially expressed genes in leiomyoma and myometrium in untreated and GnRHa-treated cohorts, respectively. The expression of 170 and 164 genes was affected by GnRHa therapy in these tissues compared with their respective untreated group. GnRHa (0.1 microm), in a time-dependent manner (2, 6, and 12 h), targeted the expression of 281 genes (P < or = 0.005) in LSMC and MSMC, 48 of which genes were found in common with GnRHa-treated tissues. Functional annotations assigned these genes as key regulators of processes involving transcription, translational, signal transduction, structural activities, and apoptosis. We validated the expression of IL-11, early growth response 3, TGF-beta-induced factor, TGF-beta-inducible early gene response, CITED2 (cAMP response element binding protein-binding protein/p300-interacting transactivator with ED-rich tail), Nur77, growth arrest-specific 1, p27, p57, and G protein-coupled receptor kinase 5, representing cytokine, common transcription factors, cell cycle regulators, and signal transduction, at tissue levels and in LSMC and MSMC in response to GnRHa time-dependent action using real-time PCR, Western blotting, and immunohistochemistry. In conclusion, using different, complementary approaches, we characterized leiomyoma and myometrium molecular fingerprints and identified several previously unrecognized genes as targets of GnRHa action, implying that local expression and activation of these genes may represent features differentiating leiomyoma and myometrial environments during growth and GnRHa-induced regression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604208     DOI: 10.1210/en.2004-1384

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells.

Authors:  Desireé M McCarthy-Keith; Minnie Malik; Joy Britten; James Segars; William H Catherino
Journal:  Fertil Steril       Date:  2011-04-15       Impact factor: 7.329

Review 2.  Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.

Authors:  Nasser Chegini
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

Review 3.  The expression and potential regulatory function of microRNAs in the pathogenesis of leiomyoma.

Authors:  Xiaoping Luo; Nasser Chegini
Journal:  Semin Reprod Med       Date:  2008-10-24       Impact factor: 1.303

4.  Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient.

Authors:  Irina K Dimitrova; Jennifer K Richer; Michael C Rudolph; Nicole S Spoelstra; Elaine M Reno; Theresa M Medina; Andrew P Bradford
Journal:  Fertil Steril       Date:  2008-07-30       Impact factor: 7.329

5.  Expression profiling of nuclear receptors identifies key roles of NR4A subfamily in uterine fibroids.

Authors:  Hanwei Yin; Jay H Lo; Ji-Young Kim; Erica E Marsh; J Julie Kim; Asish K Ghosh; Serdar Bulun; Debabrata Chakravarti
Journal:  Mol Endocrinol       Date:  2013-04-02

6.  Transforming growth interacting factor expression in leiomyoma compared with myometrium.

Authors:  Jason Yen-Ping Ho; Weng Chi Man; Yan Wen; Mary Lake Polan; Esther Shih-Chu Ho; Bertha Chen
Journal:  Fertil Steril       Date:  2009-06-13       Impact factor: 7.329

7.  miR-200c is aberrantly expressed in leiomyomas in an ethnic-dependent manner and targets ZEBs, VEGFA, TIMP2, and FBLN5.

Authors:  Tsai-Der Chuang; Harekrushna Panda; Xiaoping Luo; Nasser Chegini
Journal:  Endocr Relat Cancer       Date:  2012-07-22       Impact factor: 5.678

8.  Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids.

Authors:  Qun Pan; Xiaoping Luo; Nasser Chegini
Journal:  J Cell Mol Med       Date:  2007-12-20       Impact factor: 5.310

9.  microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.

Authors:  Qun Pan; Xiaoping Luo; Nasser Chegini
Journal:  Mol Hum Reprod       Date:  2009-11-11       Impact factor: 4.025

10.  Genomic and proteomic profiling I: leiomyomas in African Americans and Caucasians.

Authors:  Qun Pan; Xiaoping Luo; Nasser Chegini
Journal:  Reprod Biol Endocrinol       Date:  2007-08-23       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.